Biologics Contract Development And Manufacturing Organization Cdmo Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

Biologics CDMOs offer specialized services spanning cell line development, process development, clinical and commercial-scale manufacturing, analytical testing, and aseptic fill-finish for biologic drug substances and products. The market is currently estimated at approximately $23.5 billion in 2025, with growth projections clustering around an 11.3% CAGR through the next decade. The figure varies across industry sources because biologics CDMO is a private commercial segment, with no dedicated government statistical agency publishing standardized size data.

• •Service scope spans cell line development, scale-up, GMP manufacturing, and fill-finish for complex biologics
• •Sizing relies on commercial analytics because no official government body tracks biologics CDMO activity as a standalone segment
• •Demand is tied directly to the volume and complexity of biologic drugs in development and commercialization

A record number of biologic candidates in clinical pipelines is pushing sponsors to seek external capacity, particularly for monoclonal antibodies, bispecifics, antibody-drug conjugates, and cell and gene therapies that require specialized infrastructure. The loss of exclusivity for several top-selling biologics is also opening opportunities for biosimilar manufacturers, many of which rely on CDMO partners for cost-efficient production. At the same time, the capital intensity of building large-scale biomanufacturing facilities is encouraging both large and small biopharma companies to outsource rather than invest in captive plants.

• •Expansion of biologics pipelines, including mAbs, ADCs, and advanced therapy medicinal products
• •Patent cliffs for major biologics creating demand for biosimilar and biobetter development partners
• •High capital costs of biomanufacturing facilities incentivizing outsourcing over in-house production

By service type, the market spans contract development, contract manufacturing, and fill-finish operations, with manufacturing representing the largest revenue share. By molecule type, monoclonal antibodies dominate, followed by recombinant proteins, vaccines, and the rapidly growing cell and gene therapy segment. Geographically, North America holds the largest share due to its concentration of biotech firms and FDA-registered facilities, while Europe remains a mature hub, and Asia-Pacific is the fastest-growing region driven by capacity buildouts in China, South Korea, India, and Singapore.

• •Monoclonal antibodies account for the largest molecule segment, with cell and gene therapies growing fastest
• •North America leads revenue, supported by dense biotech activity and established regulatory infrastructure
• •Asia-Pacific is expanding rapidly as sponsors diversify supply chains and tap lower-cost manufacturing capacity

What are the recent trends and outlook?

The market outlook through the early 2030s is shaped by rising demand for cell and gene therapy manufacturing, the integration of single-use bioreactor platforms, and increasing adoption of digital and continuous bioprocessing technologies. Geopolitical pressures are also prompting biopharma sponsors to pursue geographic diversification of supply chains, benefiting CDMOs with multi-region footprints. Capacity for late-stage clinical and commercial biologics, particularly in Asia-Pacific, is expected to remain tight, supporting continued pricing power and long-term contracts for leading CDMOs.

• •Cell, gene, and viral vector CDMO capacity is expanding fastest, supported by rising FDA and EMA approvals
• •Adoption of single-use systems, continuous manufacturing, and process digitalization is accelerating across providers
• •Supply-chain reshoring and diversification are driving CDMO investment in the U.S., Europe, and Asia-Pacific